BioNxt Solutions (OTCMKTS:BNXTF) Stock Price Down 0.7% - What's Next?

Key Points

• BioNxt Solutions Inc. shares decreased by 0.7%, trading at $0.68 with an 87% drop in trading volume compared to the average session.
• The company has a market cap of $79.19 million and reported a PE ratio of -17.10, indicating it is currently unprofitable.
• BioNxt Solutions specializes in drug delivery systems and diagnostics, including COVID-19 tests and other healthcare solutions across several countries.

Shares of BioNxt Solutions Inc. (OTCMKTS:BNXTF - Get Free Report) traded down 0.7% on Tuesday . The company traded as low as $0.68 and last traded at $0.68. 455 shares traded hands during trading, a decline of 87% from the average session volume of 3,378 shares. The stock had previously closed at $0.69.

BioNxt Solutions Stock Performance

The stock's 50 day moving average is $0.44 and its two-hundred day moving average is $0.38.

BioNxt Solutions (OTCMKTS:BNXTF - Get Free Report) last announced its quarterly earnings results on Thursday, June 26th. The company reported ($0.01) EPS for the quarter.

BioNxt Solutions Company Profile

BioNxt Solutions Inc engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains.